Initially, the syndrome was called autoimmune polyendocrine syndrome. Based on clinical criteria, Neufeld and Blizzard in 1980 distinguished four main subtypes (
2). Later on, the term autoimmune polyendocrine syndrome was replaced by the more accurate “multiple autoimmune syndrome” because the majority of disease cases were due to non‐endocrine reasons (
1,
3). Type 3 MAS groups autoimmune thyroid disease, myasthenia gravis, thrombocytopenic purpura, and type 1 diabetes mellitus together with autoimmune skin disorders like Sjögren's syndrome, vitiligo, systemic lupus erythematosus, and dermatitis herpetiformis (
1,
4). In a retrospective analysis of 11 patients with type 3 MAS, Klisnick et al. (
5) found that 63.6% of the patients had segmental or bilateral vitiligo, and 90% presented with autoimmune thyroid disease. The authors concluded that the female sex and acrofacial topography of vitiligo, similar to those in our patient, could be used to predict associated autoimmune disorders in patients with vitiligo (
5). Vitiligo is a chronic autoimmune disease of the skin, characterized by acquired cutaneous depigmentation. The cause of this autoimmune reaction is thought to be T cell-mediated killing of melanocytes (
6), which takes place via the IFN-γ-STAT1-CXCL10 signaling inflammatory pathway (
7).
The pathogenesis of MAS remains unclear, although genetic susceptibility to environmental triggers is suspected (
8). Various autoimmunity genes such as HLA-DRB1, TNF, and PTPN22 are proposed to be associated with autoimmunity, serving an example of the effect of a single genotype on diverse phenotypes (
9,
10). Both humoral and cell-mediated immunity can play a role in MAS, presuming that if the immune system already follows the autoimmune pattern, there is a much higher possibility for another target.
The simultaneous presence of vitiligo, autoimmune thyroiditis, and diabetes mellitus in our patient suggested probable MAS. The only criterion that needed to be fulfilled to establish the diagnosis was a specific subtype of diabetes, namely late-onset autoimmune diabetes (LADA). Type 1 diabetes is classically defined as an autoimmune disease due to the destruction of pancreatic β cells in children and young adults (
11). According to some population-based analyses, however, at least 42% of type 1 diabetes cases occur after the age of 30 (
12). Distinguishing between type 1 and type 2 diabetes in middle-aged patients is challenging. Тhe reason is that in this age group, the incidence of type 2 diabetes increases rapidly, making it difficult to diagnose type 1 diabetes (
12). Unfortunately, we could not confirm the diagnosis of LADA in our patient, by examination of anti-IA and anti-GAD 65 antibodies, due to her poor compliance.